New generation of SOPHiA DDM™ integrates latest advancements in data processing and technology to deliver elevated experience and capabilities to customers.
BOSTON, United States and ROLLE, Switzerland, August 28, 2024 — SOPHiA GENETICS, a cloud-native...
Regulatory milestone validates the SOPHiA DDM™ Platform as diagnostic tool in select markets.
Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management Buffers Loss
OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™
OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™
BOSTON, United States and ROLLE, Switzerland, July 23, 2024 — SOPHiA GENETICS (Nasdaq: SOPH), a...
The diagnostics company has implemented the SOPHiA DDM™ Platform to enhance its solid tumor...
Shareholders adopt all proposals at Annual General Meeting Boston, US and Rolle, Switzerland, June...
Novel application supports measurable residual disease (MRD) testing to help monitor cancer and...
The French comprehensive cancer center implements liquid biopsy test to further its cancer...
The Hospital will use SOPHiA DDM™ to enhance its testing and research of blood cancers Boston, MA...
